Actinium Pharmaceuticals, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $48.0M | $72.9M | $76.7M | $108.9M | $77.8M | $63.6M | $9.3M | $13.7M |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $49.4M | $74.5M | $78.3M | $110.9M | $79.7M | $64.9M | $10.1M | $14.3M |
| Property, Plant & Equipment | $295.0K | $364.0K | $550.0K | $604.0K | $340.0K | $312.0K | $113.0K | $118.8K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $51.8M | $76.9M | $81.4M | $114.2M | $80.4M | $66.4M | $11.7M | $14.9M |
| Liabilities | ||||||||
| Accounts Payable | $7.2M | $7.6M | $8.0M | — | — | $4.3M | $4.6M | $5.8M |
| Total Current Liabilities | $8.0M | $8.1M | $8.5M | $10.6M | $6.8M | $4.8M | $5.3M | $6.1M |
| Long-Term Debt | — | — | — | — | — | — | $900.0K | — |
| Total Liabilities | $43.9M | $44.1M | $45.1M | $47.7M | $6.8M | $5.1M | $6.0M | $6.1M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-409.7M | $-375.8M | $-337.6M | $-288.8M | $-255.7M | $-231.0M | $-208.8M | $-186.9M |
| Total Stockholders' Equity | $7.8M | $32.8M | $36.4M | $66.5M | $73.5M | $61.3M | $5.6M | $8.8M |